Geographic Atrophy Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, by DelveInsight | Ionis Pharmaceuticals, Apellis, Annexon Inc., Genentech, Alexion, AstraZeneca

The Geographic Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Geographic Atrophy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Geographic Atrophy Market.

Some of the key takeaways from the Geographic Atrophy Pipeline Report:

• Companies across the globe are diligently working toward developing novel Geographic Atrophy treatment therapies with a considerable amount of success over the years. 
• Geographic Atrophy companies working in the treatment market are Complement Therapeutics, Aevitas Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, and others, are developing therapies for the Geographic Atrophy treatment 

• Emerging Geographic Atrophy therapies in the different phases of clinical trials are- CTx001, AAV.sFH, MCO 020, ONL 1204, RO7303359, NGM621, ANX 007, OpRegen, Pegcetacoplan, Avacincaptad, and others are expected to have a significant impact on the Geographic Atrophy market in the coming years.   
• In July 2022, The US FDA accepted and granted Priority Review designation for the intravitreal pegcetacoplan New Drug Application (NDA), according to an announcement from Apellis Pharmaceuticals.
• In October 2022, The CATALINA Phase II Trial of NGM621 in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration has reported topline results, according to NGM Bio. The primary endpoint of a statistically significant rate of change in the Geographic Atrophy lesion area over a 52-week period for NGM621 versus sham did not occur in the trial
• Ashkan Abbey, MD of Texas Retina Associates in Dallas announced the AVD-104 in its Phase 2 SIGLEC Trial by Aviceda Therapeutics, a private clinical-stage biotech company focused on developing next generation immuno-modulators by leveraging the power of glycobiology to alleviate chronic, non-resolving inflammation. This lead intravitreal asset is a new glycan-coated nanoparticle used to treat geographic atrophy (GA), a complication of age-related macular degeneration (AMD), and is supported by a particularly high pre-clinical in vivo effectiveness and safety profile.
• Patients with geographic atrophy (GA) have improved retinal structure, according to findings from a Phase I/IIa study using OpRegen (RG6501). In an exclusive partnership, Lineage, Roche, and Genentech are developing OpRegen to treat GA secondary to age-related macular degeneration (AMD).

Get a Free Sample PDF Report to know more about Geographic Atrophy Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/geographic-atrophy-ga-pipeline-insight

Emerging Geographic Atrophy Drugs Under Different Phases of Clinical Development Include:

• CTx001: Complement Therapeutics
• AAV.sFH: Aevitas Therapeutics
• MCO 020: Nanoscope Therapeutics
• ONL 1204: ONL Therapeutics
• RO7303359: Roche
• NGM621: NGM Biopharmaceuticals
• ANX 007: Annexon
• OpRegen: Genentech
• Pegcetacoplan: Apellis Pharmaceuticals
• Avacincaptad: Pegol Iveric Bio
• Zimura: Iveric bio
• RO7171009: Genentech
• RG6147: Roche
• IONIS-FB-LRx: Ionis Pharmaceuticals
• NGM621: NGM Biopharmaceuticals
• Elamipretide: Stealth BioTherapeutics
• CPCB-RPE1: Regenerative Patch Technologies
• OpRegen: CellCure Neurosciences/ Lineage Cell Therapeutics/ Roche
• PPY988/GT005: Novartis
• CPCB-RPE1: Regenerative Patch Technologies
• RPESC-RPE-4W: Luxa Biotechnology

Route of Administration

Geographic Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Molecule Type

Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy 

Geographic Atrophy Pipeline Therapeutics Assessment

• Geographic Atrophy Assessment by Product Type
• Geographic Atrophy By Stage and Product Type
• Geographic Atrophy Assessment by Route of Administration
• Geographic Atrophy By Stage and Route of Administration
• Geographic Atrophy Assessment by Molecule Type
• Geographic Atrophy by Stage and Molecule Type

DelveInsight’s Geographic Atrophy Report covers around 25+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Geographic Atrophy product details are provided in the report. Download the Geographic Atrophy pipeline report to learn more about the emerging Geographic Atrophy therapies

Some of the key companies in the Geographic Atrophy Therapeutics Market include:

Key companies developing therapies for Geographic Atrophy are – Iveric Bio (formerly Ophthotech Corporation), Ionis Pharmaceuticals, Apellis Pharmaceuticals, Inc., NGM Biopharmaceuticals, Annexon Inc., Genentech, Alexion AstraZeneca Rare Disease, ONL Therapeutics, Alkeus Pharmaceuticals, Regenerative Patch Technologies, LLC, Astellas Pharma Inc, Gemini Therapeutics, Boehringer Ingelheim, Cell Cure Neurosciences LTD, Stealth BioTherapeutics Inc., Hemera Biosciences LLC, Gyroscope Therapeutics Limited, Eyevensys, Nanoscope Therapeutics, Inc., Catalyst Biosciences, Novartis, and others.

Geographic Atrophy Pipeline Analysis:

The Geographic Atrophy pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Geographic Atrophy with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Geographic Atrophy Treatment.
• Geographic Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Geographic Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Geographic Atrophy market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Geographic Atrophy drugs and therapies

Geographic Atrophy Pipeline Market Drivers

• Increase in Patient Burden, development of Novel Treatments, increased Focus on Disease Management and early Diagnosis are some of the important factors that are fueling the Geographic Atrophy Market.

Geographic Atrophy Pipeline Market Barriers

• However, high Cost of Treatment, side-effects associated and other factors are creating obstacles in the Geographic Atrophy Market growth.

Scope of Geographic Atrophy Pipeline Drug Insight    

• Coverage: Global
• Key Geographic Atrophy Companies: Complement Therapeutics, Aevitas Therapeutics, ONL Therapeutics, Roche, NGM Biopharmaceuticals, Annexon, Genentech, Apellis Pharmaceuticals, and others
• Key Geographic Atrophy Therapies: CTx001, AAV.sFH, MCO 020, ONL 1204, RO7303359, NGM621, ANX 007, OpRegen, Pegcetacoplan, Avacincaptad, and others
• Geographic Atrophy Therapeutic Assessment: Geographic Atrophy current marketed and Geographic Atrophy emerging therapies
• Geographic Atrophy Market Dynamics: Geographic Atrophy market drivers and Geographic Atrophy market barriers 

Request for Sample PDF Report for Geographic Atrophy Pipeline Assessment and clinical trials

Table of Contents

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services